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Mechanism involved in bradykinin-induced efferent arteriole and water excretion, blood pressure, and renin release
dilation. [1–3]. Although bradykinin is known to cause renal vaso-
Background. There is evidence that kinins play a role in the dilation, its precise site of action in the renal microvascu-regulation of renal hemodynamics. The balance of vascular
lature is unclear. Thomas et al demonstrated that intra-resistance in afferent and efferent arterioles (Af-Art and Ef-
arterial infusion of bradykinin primarily reduced renal pre-Art) is a crucial factor in controlling glomerular filtration. We
have previously reported that bradykinin has a biphasic effect glomerular resistance in superficial nephrons and caused
on the Af-Art and that dilation and constriction are due to a slight decrease in post-glomerular resistance [4]. In
cyclooxygenase products, not nitric oxide (NO). The present
contrast, in isolated renal microvessels, bradykinin isstudy was designed to examine (1) the direct effect of bradyki-
thought to induce selective Ef-Art dilation [5]. Kon etnin on the Ef-Art and (2) the mechanisms that mediate bradyki-
nin-induced Ef-Art dilation. al demonstrated that in superficial nephrons, enalapril
Methods. Isolated Ef-Arts were microperfused retrograde caused preferential Ef-Art dilation, and this effect was
while maintaining the Ef-Art pressure at 30 mm Hg. Isolated offset by a bradykinin antagonist [6]. The endothelium
Ef-Arts were preconstricted with norepinephrine.
is an important component of the vasculature that isResults. Perfusing the Ef-Art lumen with bradykinin caused
critically involved in maintenance of organ perfusion.dose-dependent vasodilation, increasing diameter from 6.9 
0.7 to 8.0  0.8 (0.01 nmol/L), 8.3  0.7* (0.1 nmol/L), 10.3  Endothelial cells produce a wide array of biologically
0.7* (1 nmol/L) and 11.5  0.8* m (10 nmol/L; N  8; *P  active agents, including nitric oxide (NO), prostaglandins
0.05 vs. NE). Neither L-NAME nor indomethacin blocked the (PGs) and P450-arachidonic acid products, which regu-vasodilator effect of bradykinin; the diameter increased from
late vascular tone [7–9]. The vasodilator action of brady-8.1  0.9 to 12.9  0.6 m (10 nmol/L; P  0.05 vs. control;
N  6) in the L-NAME-treated group and from 7.4  0.9 to kinin is endothelium-dependent. We have reported that
11.0  1.0 m (10 nmol/L; P  0.05 vs. control; N  6) in the in the microperfused Af-Art kinins have a vasodilator
indomethacin-treated group. However, 25 mol/L 17-ODYA, effect that is mediated by PGs, while at higher concentra-
a cytochrome cP450 inhibitor, blocked the vasodilator effect
tions they have a vasoconstrictor effect that is mediatedof 108 mol/L bradykinin, leaving diameter unchanged (from
by thromboxane [10]. Collectively, the renal microvascu-7.9 0.8 to 7.7 0.7 m; N 6). Finally, 0.1 mol/L icatibant,
a B2 receptor antagonist, completely blocked the vasodilation lar actions of bradykinin may vary depending on the
induced by bradykinin, and the diameter went from 7.8  0.7 vascular segment involved.
to 8.3  0.8 m (10 nmol/L). In the present study, we examined (1) the direct effectConclusions. Bradykinin dilates Ef-Arts, but in contrast to
of bradykinin on the Ef-Art and (2) the mechanismsAf-Arts its effect is not biphasic. The vasodilator effect of
that mediate bradykinin-induced actions. To clarify thesebradykinin in Ef-Arts via B2 receptors is mediated by cP450
metabolites (probably EETs), but not by NO or cyclooxygen- important issues, we employed a novel approach to di-
ase products. rectly visualize the Ef-Art. The Ef-Art was isolated and
microperfused retrograde to eliminate the influence of
the glomerulus. In addition, there are no systemic hemo-
The kallikrein-kinin system is involved in the regula- dynamic or hormonal influences in our preparation, mak-
tion of renal hemodynamics, and thus influences sodium ing it ideal to study the direct effect of bradykinin on
the Ef-Art.
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with ketamine (50 mg/kg IM) and pentobarbital (30 Ann Arbor, MI, USA) was prepared in dimethyl sulfox-
mg/kg IV) and the kidneys removed. The kidneys were ide (DSMO). The final DSMO concentration was
sliced along the corticomedullary axis and the slices 0.0025%, which had no effect. 17-ODYA (25 mol/L)
placed in ice-cold minimum essential medium (MEM; was added to the lumen, and the effect of bradykinin
Gibco, Grand Island, NY, USA) containing 5% bovine was examined as in Protocol 2. 17-ODYA reportedly
serum albumin (BSA; Sigma, St. Louis, MO, USA). A has a half-maximal inhibitory concentration (IC50) of 10
single superficial Ef-Art with glomerulus and Af-Art mol/L, which effectively blocked the formation of epox-
intact was microdissected under a stereomicroscope yeicosatrienoic acid (EET) [13].
(SZH; Olympus, Tokyo, Japan). Using a micropipette, Protocol 4. Effect of cyclooxygenase inhibition on bra-
the arteriole was transferred to a temperature-regulated dykinin-induced dilation. We examined whether vasodi-
chamber mounted on an inverted microscope (IMT-2; lator prostaglandins mediate bradykinin-induced dila-
Olympus) with Hoffmann modulation. Ef-Arts (100 to tion. The protocol was the same as Protocol 2 except
150 m) were perfused from the distal end (retrograde) that indomethacin (Indo; 50 mol/L; Sigma) was added
with oxygenated MEM containing 5% BSA. Since most to both bath and lumen. Indomethacin was dissolved
of the Af-Art was removed, there was no influence by in saline containing 1.15 mg/mL sodium carbonate at 5
the glomerulus. Perfusion pressure was maintained at 30 mmol/L and diluted with luminal perfusate or bath solu-
mm Hg. tion to 50 mol/L. We confirmed that the vehicle had
The bath, which was exchanged continuously, was no effect. We have previously shown that this dose of
identical to the arteriolar perfusate except that it con- indomethacin blocks the effect of arachidonic acid (0.1
tained 0.15% BSA. Microdissection and cannulation mmol/L) on renin release in rabbit afferent arterioles [14].
were completed within 90 minutes at 8C, after which Protocol 5. Effect of NO synthesis inhibition on brady-
the bath was gradually warmed to 37C. Following a 30- kinin-induced dilation. To examine whether nitric oxide
minute equilibration period, images of the Ef-Art were (NO) mediates bradykinin-induced dilation, in a sepa-
displayed at magnifications up to 1980 and recorded rate experiment 100 mol/L NG-nitro-l-arginine methyl
with a video system consisting of a camera (DXC-755; ester (L-NAME), an NO synthesis inhibitor, was added
Sony, Tokyo, Japan), monitor (PVM1942q; Sony), and to the preconstricted efferent arteriole lumen and the
video recorder (EDV-9500; Sony). Diameter was mea- effect of bradykinin was examined. This concentration
sured with an image analysis system (Universal Imaging, of L-NAME abolished acetylcholine-induced dilation of
West Chester, PA, USA). rabbit Ef-Arts [12].
Experimental protocols
Statistics
Protocol 1. Response of preconstricted Ef-Arts to bra-
Values were expressed as mean  SE. Analysis ofdykinin. The vasodilator action of bradykinin was exam-
variance (ANOVA) was used to analyze overall change,ined in preconstricted Ef-Arts because the isolated Ef-
using dose as the repeated measure. Each dose was com-Art has little intrinsic tone. After a 30-minute equilibra-
pared to baseline or NE preconstriction using a pairedtion period, Ef-Arts were preconstricted by 40% with
t test, whereas a two-sided t test (or Welch’s test, ifnorepinephrine (NE; Sigma), and bradykinin (0.01 to 10
variances were unequal) was used to examine whethernmol/L) was added to the lumen. Luminal diameter was
changes in diameter at a given concentration differedmeasured immediately before adding bradykinin and
between groups. P  0.05 was considered significant.monitored for at least 10 minutes at each dose.
Protocol 2. Effect of bradykinin B2 receptor inhibition
on bradykinin-induced dilation. To discover which re- RESULTS
ceptor is involved in bradykinin-induced dilation, the Ef-
Response of preconstricted Ef-Arts to bradykinin
Art was perfused retrograde, and a dose-response curve
Pretreatment with NE reduced basal Ef-Art diameterwas generated with bradykinin as in protocol 1. The
by 43.4% (from 12.2  0.7 to 6.9  0.7 m; N  8).perfusate was then replaced with a bradykinin-free solu-
Adding 0.01 to 10 nmol/L bradykinin to the lumen di-tion. Then, icatibant (0.1mol/L; Bachem Co., Torrence,
lated Ef-Arts in a dose-dependent manner. The maxi-CA, USA) was added to the lumen and a second bradyki-
mum dilation occurred at 10 nmol/L, increasing diameternin dose-response curve generated. This concentration
from 6.9  0.7 to 11.5  0.8 m (Fig. 1). In separateof icatibant was found to block bradykinin (10 nmol/L)-
experiments, dose-response curves for bradykinin wereinduced afferent arteriole dilation [10].
repeated but no statistically significant change was foundProtocol 3. Effect of cP450 inhibition on bradykinin-
in bradykinin-induced dilation of preconstricted Ef-Arts.induced dilation. To determine whether cP450 metabo-
First, the diameter went from 8.1  0.6 to 8.2  0.1,lites mediate bradykinin-induced dilation, a stock solution
of 17-octadecenoic acid (17-ODYA; Cayman Chemical, 8.8  0.03, 10.6  0.3 and 11.8  0.4 m; second, the
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Fig. 2. Effect of inhibition of the bradykinin B2 receptor on bradykinin-Fig. 1. Response of preconstricted efferent arterioles (Ef-Arts) to bra-
induced Ef-Art dilation. Icatibant completely blocked bradykinin-dykinin. Bradykinin caused dose-dependent vasodilation (N  8; *P 
induced dilation (N  6). Symbols are: () untreated; () icatibant 0.10.05 vs. control).
mol/L; *P  0.05, nontreated vs. icatibant-treated.
diameter went from 7.9  0.3 to 8.0  0.2, 9.3  0.4,
11.2  0.4 and 12.2  0.5 m.
Effect of bradykinin B2 receptor inhibition on
bradykinin-induced dilation
Most of the vascular actions of bradykinin are report-
edly mediated by B1 and B2 receptors. To investigate the
ability of the B2 receptor antagonist icatibant to block
the effects of bradykinin, 0.1 mol/L icatibant was added
to the perfusate, and Ef-Arts were preconstricted with
NE. In the untreated group, bradykinin at 0.1, 1 and
10 nmol/L dilated the Ef-Art, increasing the luminal
diameter from 8.4  0.8 to 9.3  0.9, 11.1  0.5, and
12.0 0.7 m, respectively (P  0.01; N 6). However,
icatibant completely blocked the vasodilation induced
by bradykinin; diameter went from 7.8  0.7 to 7.9 
0.8, 7.9  0.8, and 8.3  0.8 m, respectively (Fig. 2).
Effect of cP450 inhibition on bradykinin-
Fig. 3. Effect of cP450 inhibition on bradykinin-induced Ef-Art dila-induced dilation
tion. When 17-octadecenoic acid (17-ODYA; 2.5  105 mol/L) was
First, the contribution of cP450 metabolites to bradyki- added to the Ef-Art lumen, bradykinin-induced dilation was completely
abolished (N  6). Symbols are: () untreated; () 17-ODYA 25nin-induced vasodilation was investigated. The basal di-
mol/L; *P  0.05, nontreated vs. 17-ODYA-treated.ameter was 14.3  0.4 m and this remained unchanged
following pretreatment with 17-ODYA (25 mol/L).
However, it completely abolished bradykinin-induced
Ef-Art dilation, with the luminal diameter being 7.7 
12.1  0.9 m (n  6), and did not change when indo-0.7, 7.4  0.6 and 7.7  0.7 m at 0.1, 1 and 10 nmol/L,
methacin was added to the bath and lumen. The diameterrespectively (Fig. 3).
before and after treatment was 12.1  0.9 and 11.9 
Effect of cyclooxygenase inhibition on bradykinin- 0.9 m. Indomethacin had no effect on the vasodilation
induced dilation induced by bradykinin; the diameter increased from
7.4  0.9 to 9.2  1.0, 10.6  0.9 and 11.0  1.0 m atThe role of prostaglandins in mediating bradykinin-
induced dilation was examined. Basal diameter was 0.1, 1, and 10 nmol/L, respectively (Fig. 4).
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Fig. 4. Effect of cyclooxygenase inhibition on bradykinin-induced Ef-
Art dilation. Indomethacin pretreatment had no effect on bradykinin
Fig. 5. Effect of nitric oxide (NO) synthesis inhibition on bradykinin-action (N  6). Symbols are: () untreated; () indomethacin 50
induced Ef-Art dilation. L-NAME pretreatment did not block bradyki-mol/L.
nin-induced dilation (N 6). Symbols are: () untreated; () L-NAME
100 mol/L.
Effect of NO synthesis inhibition on bradykinin-
induced dilation how bradykinin directly affects the Ef-Art. Bradykinin
stimulates the release of vasodilator PGs from culturedBecause bradykinin is known to dilate other vascular
endothelial cells [19]. There is evidence that the natri-beds by stimulating NO release, we next tested whether
uretic and diuretic effects of kinins infused into the renalNO mediates bradykinin-induced Ef-Art dilation. Figure
arteries of dogs pretreated with cyclooxygenase inhibi-5 illustrates changes in luminal diameter induced by bra-
tors are mediated by NO [20], and that the renal effectsdykinin in L-NAME-pretreated and NE-preconstricted
of kinins are also mediated by PGs [21]. To examineEf-Arts, compared with Protocol 1. The basal diameter
this issue, we studied the effects of NO synthase andwas 13.0  0.7 m (N  6). L-NAME had no effect on
cyclooxygenase inhibitors on bradykinin-induced vaso-preconstricted Ef-Art diameter. After pretreatment with
dilation and found that it was not affected by either100 mol/L L-NAME and NE, however, the diameter
L-NAME or indomethacin, suggesting that NO anddecreased to 8.5 0.5m. Bradykinin dilated L-NAME-
cyclooxygenase metabolites have little influence on thetreated Ef-Arts to the same extent as those not treated
action of bradykinin in the Ef-Art. Our previous studywith L-NAME; the luminal diameter increased from
showed that pretreating Af-Arts with L-NAME failed8.5  0.5 to 10.9  0.5, 11.9  0.6, and 12.3  0.8 m
to affect their response to bradykinin [10]. Quilley et alat 0.1, 1, and 10 nmol/L, respectively.
also reported that bradykinin-induced vasodilation was
endothelium-dependent but NO-independent [22]. In
DISCUSSION the heart, the vasodilator response to bradykinin is inde-
This study examined the direct effects of bradykinin pendent of both NO and PGs.
on the rabbit Ef-Art, as well as its mechanism of action. Bradykinin stimulates phospholipases to release arach-
We found that in the isolated microperfused Ef-Art, idonic acid, which can be metabolized by cyclooxygen-
unlike the Af-Art, bradykinin causes dose-dependent ase, lipoxygenase and cytochrome P450 to yield vaso-
vasodilation via the B2 receptor, which is mediated by active products that may contribute to its effect. We
cP450 metabolites (probably EETs) but not by cyclooxy- found that when preconstricted Ef-Arts were perfused
genase metabolites or NO. retrograde, neither indomethacin nor L-NAME altered
Renal kinins are released by kallikrein at both the the vasodilator response to bradykinin; however, it was
luminal and basolateral sides of the nephron [15, 16]. blocked by 17-ODYA, a cP450 metabolite antagonist.
Kallikrein is located mainly in the connecting tubule These data suggest that the vasodilation produced by
[17, 18], which is situated close to the glomerular tuft, bradykinin is mediated by cP450 metabolites, probably
and kinins released from this segment could regulate EETs. Our studies in the rabbit Ef-Art are consistent
with a cP450-derived metabolite of arachidonic acid be-both the Af-Art and Ef-Art. However, it is not clear
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ing involved in the NO-independent response, which is angiotensin-converting enzyme (ACE) inhibitor, a bra-
dykinin antagonist markedly blunted increased papillarysupported by several recent reports [23–26]. The iso-
lated, perfused rat kidney studies of Fulton, McGiff and blood flow originating from the juxtamedullary neph-
rons, but had only a modest effect on cortical blood flowQuilley also suggest that a cP450 arachidonic acid metab-
olite contributes to the bradykinin-induced decrease in [39]. Recently, Matsuda et al reported that in superficial
nephrons, bradykinin stimulated by the ACE inhibitorrenal perfusion pressure [7]. Moreover, EETs produced
by the endothelium have been shown to elicit vasodila- cilazaprilat dilated the Ef-Art but not the Af-Art [40].
In the present study, unlike the Af-Art, bradykinin di-tion [24–26]; renal microvascular EET levels were in-
creased by bradykinin in the incubation medium [27]. lated the Ef-Art in a dose-dependent manner. The differ-
ence in Af-Art and Ef-Art responses is not unique toWe are aware that 17-ODYA has a lower IC50 for 19/
20-HETE. We confirmed that 20-HETE constricted the bradykinin; for example, Ang II constricts the Ef-Art
more than the Af-Art [12], while adenosine constrictsefferent arteriole (unpublished data), but did not dilate
it. A low concentration of 17-ODYA (5 mol/L), which Af-Arts and dilates Ef-Arts via activation of A1 and
A2 receptors, respectively [41] [abstract; Ren Y et al,inhibited 19/20-HETE but not EET production, did not
influence bradykinin-induced vasodilation (unpublished J Hypertens 12(Suppl 3):S160, 1994]. Thus the renal mi-
crovascular action of bradykinin may vary depending ondata). Taken together, bradykinin-induced Ef-Art dila-
tion is not mediated by 20-HETE, but is possibly medi- the vascular segment(s) involved and the location of the
nephrons.ated by vasodilator EETs. Although our results clearly
demonstrate that cP450 epoxygenase metabolites are in- In summary, we examined the direct effect of bradyki-
nin on the Ef-Art in the presence and absence of para-volved in the renal microvascular response to bradykinin,
the identity of the epoxide metabolites remains unre- crine/autacoid hormones. Our results suggest that brady-
kinin dilates the Ef-Art, but unlike the Af-Art its effectsolved. Renal vascular resistance is decreased by adding
5,6-EET, 8,9-EET or 11,12-EET to the perfusate of iso- is not biphasic. The vasodilator effect of bradykinin on
the Ef-Art via B2 receptors is mediated by cP450 metabo-lated, perfused rabbit kidneys [28, 29]. Additionally,
11,12-EET appears to dilate the Af-Art by increasing lites (probably EETs), but not by NO or cyclooxygenase
products. Formation of vasodilator eicosanoids derivedcalcium-activated K channel activity following cAMP
stimulation of protein kinase A [30, 31]. Thus 5,6-EET via the cP450 pathway may be important for control of
vascular tone and local blood flow, and hence glomerularand 11,12-EET may be involved in the renal vasodilator
response to bradykinin. hemodynamics.
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